Stereotaxis (STXS): Price and Financial Metrics
STXS Price/Volume Stats
| Current price | $2.14 | 52-week high | $2.75 |
| Prev. close | $2.17 | 52-week low | $1.55 |
| Day low | $2.10 | Volume | 94,600 |
| Day high | $2.17 | Avg. volume | 230,175 |
| 50-day MA | $1.89 | Dividend yield | N/A |
| 200-day MA | $2.04 | Market Cap | 172.65M |
STXS Stock Price Chart Interactive Chart >
STXS POWR Grades
- Momentum is the dimension where STXS ranks best; there it ranks ahead of 64.12% of US stocks.
- STXS's strongest trending metric is Stability; it's been moving down over the last 179 days.
- STXS's current lowest rank is in the Sentiment metric (where it is better than 26.22% of US stocks).
STXS Stock Summary
- For STXS, its debt to operating expenses ratio is greater than that reported by merely 18.8% of US equities we're observing.
- With a price/sales ratio of 6.15, STEREOTAXIS INC has a higher such ratio than 82.89% of stocks in our set.
- Revenue growth over the past 12 months for STEREOTAXIS INC comes in at -17.28%, a number that bests only 12.59% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to STEREOTAXIS INC are RSKD, DOMO, S, IRNT, and BNR.
- Visit STXS's SEC page to see the company's official filings. To visit the company's web site, go to www.stereotaxis.com.
STXS Valuation Summary
- In comparison to the median Healthcare stock, STXS's price/sales ratio is 172.73% higher, now standing at 6.
- Over the past 229 months, STXS's price/sales ratio has gone down 12.6.
Below are key valuation metrics over time for STXS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STXS | 2023-05-23 | 6.0 | 7.0 | -8.0 | -8.3 |
| STXS | 2023-05-22 | 6.3 | 7.4 | -8.3 | -8.7 |
| STXS | 2023-05-19 | 6.6 | 7.7 | -8.7 | -9.0 |
| STXS | 2023-05-18 | 4.9 | 5.7 | -6.5 | -6.8 |
| STXS | 2023-05-17 | 4.9 | 5.7 | -6.5 | -6.8 |
| STXS | 2023-05-16 | 5.1 | 6.0 | -6.8 | -7.0 |
STXS Growth Metrics
- Its 2 year revenue growth rate is now at 20.93%.
- Its 4 year net cashflow from operations growth rate is now at 6.66%.
- Its year over year net cashflow from operations growth rate is now at -192.75%.
The table below shows STXS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 29.08643 | -7.918919 | -18.83483 |
| 2022-06-30 | 30.53588 | -6.005304 | -18.53611 |
| 2022-03-31 | 33.4353 | -4.833745 | -14.61271 |
| 2021-12-31 | 35.02086 | -2.945911 | -12.06065 |
| 2021-09-30 | 33.60519 | -0.582029 | -9.889141 |
| 2021-06-30 | 33.20232 | -0.445619 | -6.847937 |
STXS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STXS has a Quality Grade of B, ranking ahead of 89.02% of graded US stocks.
- STXS's asset turnover comes in at 0.581 -- ranking 75th of 186 Medical Equipment stocks.
- FONR, SMLR, and KIDS are the stocks whose asset turnover ratios are most correlated with STXS.
The table below shows STXS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.581 | 0.676 | -2.014 |
| 2021-03-31 | 0.516 | 0.684 | -1.715 |
| 2020-12-31 | 0.504 | 0.712 | -1.512 |
| 2020-09-30 | 0.536 | 0.708 | -1.279 |
| 2020-06-30 | 0.565 | 0.786 | -0.976 |
| 2020-03-31 | 0.739 | 0.795 | -0.864 |
Stereotaxis (STXS) Company Bio
Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control system for use in the cath lab that is used in the treatment of coronary artery disease and arrhythmias. The Company markets Stereotaxis System in the United States and Europe.
Latest STXS News From Around the Web
Below are the latest news stories about STEREOTAXIS INC that investors may wish to consider to help them evaluate STXS as an investment opportunity.
Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor ConferenceST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference. Mr. Fischel will be available on Wednesday, May 31, 2023 for one-on-one meetings with conference attendees. “We appreciate the invitation by Craig-Hallum and look forward to sharing Stereotaxis’ |
Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic TechnologyST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Advocate Christ Medical Center in Chicago, Illinois. Advocate Christ Medical Center, a part of Advocate Health, is the leading provider of robotic heart rhythm care in the Midwest. Electrophysiologists at the hospital have t |
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation CatheterStereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months. Concurr |
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart RhythmsST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. Technology integr |
Q1 2023 Stereotaxis Inc Earnings CallQ1 2023 Stereotaxis Inc Earnings Call |
STXS Price Returns
| 1-mo | 23.70% |
| 3-mo | -1.38% |
| 6-mo | 5.94% |
| 1-year | -3.60% |
| 3-year | -55.97% |
| 5-year | 182.32% |
| YTD | 3.38% |
| 2022 | -66.61% |
| 2021 | 21.81% |
| 2020 | -3.78% |
| 2019 | 389.36% |
| 2018 | 35.13% |
Continue Researching STXS
Want to see what other sources are saying about Stereotaxis Inc's financials and stock price? Try the links below:Stereotaxis Inc (STXS) Stock Price | Nasdaq
Stereotaxis Inc (STXS) Stock Quote, History and News - Yahoo Finance
Stereotaxis Inc (STXS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...